BCRXBioCryst Pharmaceuticals, Inc.
Is the business good?
The checks split: 7 of 9 health tests passed, but margins compressing.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is BCRX?
BioCryst Pharmaceuticals, Inc. keeps −33% of every revenue dollar as operating profit, against 11% for the median Drug Manufacturers - Specialty & Generic name.
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q2 2026
- Share count, year on year
- +21%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 21%
R&D as % of revenue
- Gross margin
- 98%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −981% |
| FY2021 | −113% |
| FY2022 | −55% |
| FY2023 | −31% |
| FY2024 | −0.56% |
| FY2025 | 39% |
Details›
- Gross margin12 months to Q2 2026
- 98%
- Operating margin12 months to Q2 2026
- −33%
- Net margin12 months to Q2 2026
- −41%
- Free cash flow margin
- 40%
- R&D as % of revenue
- 21%
- Revenue, trailing twelve months
- $941M
- Free cash flow, trailing twelve months
- $373M
- Net income, trailing twelve months
- −$385M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #41 of 41 by RyuScore